novel hepatitis c virus inhibitor combinations comprising an hcv protease inhibitor and hcv polymerase inhibitor , and optionally one or more biologically active agents , as well as uses of these combinations as hcv inhibitors and for treating hepatitis c and related disorders are disclosed .